New Drug SRN-901 Extends Mouse Lifespan 33% While Cutting Frailty by 70%
Seragon's oral combo therapy SRN-901 outperforms rapamycin in mice, boosting lifespan and slashing frailty through multi-pathway aging intervention.
Summary
A new investigational drug called SRN-901, developed by Seragon Biosciences, extended median remaining lifespan by 33% in adult mice while reducing frailty progression by 70%. The oral combination therapy contains urolithin A, quercetin, nicotinamide riboside, alpha-lipoic acid, and a proprietary compound called SRN-820. Unlike single-target approaches, SRN-901 works across multiple aging pathways simultaneously — addressing inflammation, DNA damage, metabolism, and cellular stress at once. It also reduced tumor incidence by over 30%. The drug outperformed rapamycin, which achieved only a 21% lifespan extension in the same study. These are preclinical results in mice, not humans, but the findings suggest that combination therapies targeting aging's complexity may be more effective than single-compound approaches.
Detailed Summary
Seragon Biosciences has released preclinical data on SRN-901, an oral combination therapy that extended median remaining lifespan by 33% in adult mice — a headline figure that immediately sets it apart from most longevity compounds tested to date. More importantly, the mice didn't just live longer; they aged better, maintaining posture, grooming, and physical function well into old age.
The drug's multi-compound formula includes urolithin A, quercetin, nicotinamide riboside, alpha-lipoic acid, and Seragon's proprietary SRN-820. This combination was designed to act on several aging pathways simultaneously rather than targeting a single mechanism. The study's multi-omic analysis — examining gene expression, proteins, and metabolism together — showed SRN-901 upregulated DNA repair pathways while suppressing inflammation and cellular stress responses, effectively shifting the metabolic profile of older mice toward a younger biological state.
The results outpaced well-known longevity interventions. Rapamycin, one of the most studied lifespan-extending drugs, achieved a 21% increase in the same study. Popular NAD+ precursors like NMN and NR showed no significant lifespan benefit. Frailty progression — a composite measure of physical decline — was reduced by 70%, and tumor incidence dropped by over 30%, suggesting broad protective effects against age-related disease.
The findings support a growing consensus in longevity science: aging is not a single-pathway problem. It is a network of interconnected failures, and interventions that address only one node may be inherently limited. SRN-901's design philosophy — targeting the system rather than a single component — appears to produce meaningfully better outcomes in this model.
Critical caveats apply. These are mouse data, and the history of longevity research is littered with promising preclinical results that failed to translate to humans. No human trials have been announced. The proprietary SRN-820 compound remains undisclosed, limiting independent evaluation. Still, the study's rigor and the magnitude of results make it a meaningful data point in the field.
Key Findings
- SRN-901 extended median remaining lifespan by 33% in adult mice, outperforming rapamycin's 21% in the same study
- Frailty progression was reduced by 70%, meaning treated mice maintained physical function significantly longer into old age
- Tumor incidence dropped by 30.53%, suggesting broad protection against age-related disease beyond just lifespan extension
- Multi-omic analysis showed SRN-901 boosted DNA repair and suppressed inflammation, shifting older mice toward a younger metabolic profile
- NMN and NR showed no significant lifespan benefit in this study, challenging their standalone use as longevity interventions
Methodology
This is a news report summarizing preclinical findings published by Seragon Biosciences on their investigational compound SRN-901. The source, Longevity.Technology, is a credible industry publication covering aging science, though it has commercial relationships with some biotech firms. Evidence is based on animal (mouse) data with multi-omic analysis; no peer-reviewed publication link or journal citation is confirmed in the article text.
Study Limitations
Results are preclinical mouse data only and may not translate to human outcomes; this is a known and recurring limitation in longevity drug development. The proprietary SRN-820 component is not publicly characterized, preventing independent replication or evaluation of its contribution. The primary research paper should be reviewed directly to assess study design, mouse strain, dosing, and statistical methodology before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.